PRIMARY STUDY
Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis
Key Findings: This meta-analysis concludes that urinary liver-type fatty acid-binding protein (uL-FABP) could be used as a biomarker for the detection of all stages of diabetic nephropathy and in predicting progression and severity in patients with both type 1 and type 2 diabetes mellitus.
Type of Study: Clinical Meta-analysis
Study Sample Size: 13
Study Result: Positive
Research Location(s): China
Year of Pub: 2022
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Route of Administration: Endogenous
Citation: Zhang L, et al. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis. Front Med (Lausanne). 2022; 9:914587. doi: 10.3389/fmed.2022.914587
Authors: Zhang L, Xue S, Wu M, Dong D
